Frank Cappelleri looks at the charts on the XLV ETF and at another fund that can help investors assess where health care will go.
Category: Uncategorized
Tired of politics? Here are some controversial stocks to argue about over Thanksgiving dinner
CNBC Pro screened the S&P 1500 index for those large- and midcap securities that are the most divisive on Wall Street.
These stocks have strong total shareholder returns, says Morgan Stanley
Morgan Stanley screened for names that have robust returns, including dividends and stock buybacks.
An options trade that makes money as people try to get fit after the holidays
Michael Khouw breaks down this call spread trade on this fitness stock.
JPMorgan upgrades air filtration stock after $450 million deal announced this week
JPMorgan’s updated forecast calls for upside ahead of 25%.
This health tech stock is a buy and can surge nearly 50% from here, says Piper Sandler
Piper Sandler’s revised price target sees shares of Oscar Health soaring 49%.
Broadcom gets a price target hike from Goldman ahead of earnings next month
Goldman Sachs sees shares of Broadcom rising 13% from here.
Nvidia shares hit by report on new AI chip competition. How worried should investors be?
Competition for Nvidia’s crown in the artificial intelligence is ramping up, but analysts aren’t too worried — for now.
These stocks well liked by analysts have not panned out in 2025
Some stocks with “buy” ratings from analysts have seen their shares, earnings and income sink this year.
This organ transport stock is breaking out. Where it might go, according to the charts
Todd Gordon goes through the technicals of the health care sector and this organ transport stock.